Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer

Ebaa Al-Obeidi; Jonathan W Riess; Umberto Malapelle; Christian Rolfo; David R Gandara

doi:10.1016/j.hoc.2023.02.005

Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer

Hematol Oncol Clin North Am. 2023 Jun;37(3):475-487. doi: 10.1016/j.hoc.2023.02.005. Epub 2023 Apr 4.

Authors

Ebaa Al-Obeidi¹, Jonathan W Riess², Umberto Malapelle³, Christian Rolfo⁴, David R Gandara⁵

Affiliations

¹ Division of Hematology-Oncology, University of California, Davis, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA. Electronic address: ealobeidi@ucdavis.edu.
² Division of Hematology-Oncology, University of California, Davis, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA.
³ Department of Public Health, University of Naples Federico II, Via Sergio Pansini 5, 80131, Naples, Italy. Electronic address: https://twitter.com/UmbertoMalapel1.
⁴ Center for Thoracic Oncology at the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, Box 1079, New York, NY 10029, USA. Electronic address: https://twitter.com/ChristianRolfo.
⁵ Division of Hematology-Oncology, University of California, Davis, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA. Electronic address: https://twitter.com/drgandara.

PMID: 37024388
DOI: 10.1016/j.hoc.2023.02.005

Abstract

This review article illuminates the role of liquid biopsy in the continuum of care for non-small cell lung cancer (NSCLC). We discuss its current application in advanced-stage NSCLC at the time of diagnosis and at progression. We highlight research showing that concurrent testing of blood and tissue yields faster, more informative, and cheaper answers than the standard stepwise approach. We also describe future applications for liquid biopsy including treatment response monitoring and testing for minimal residual disease. Lastly, we discuss the emerging role of liquid biopsy for screening and early detection.

Keywords: Circulating tumor DNA (ctDNA); Liquid biopsy; Minimal residual disease (MRD); Next-generation sequencing (NGS); Non-small cell lung cancer (NSCLC); Tumor mutational burden (TMB).

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers, Tumor / analysis
Carcinoma, Non-Small-Cell Lung* / diagnosis
Carcinoma, Non-Small-Cell Lung* / therapy
Circulating Tumor DNA*
Humans
Liquid Biopsy
Lung Neoplasms* / diagnosis
Lung Neoplasms* / pathology
Precision Medicine

Substances

Circulating Tumor DNA
Biomarkers, Tumor